Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438112 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
A Phase 2 study, sponsored by CG Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01438112 is a Phase 2 study that was terminated before completion, run by CG Oncology. The registered enrollment target is 22 participants.
The verdict
NCT01438112, a Phase 2 study, was terminated before completion, sponsored by CG Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of the immune system for local cancer cell death as well as destroying those tumor cells that may have travelled to regional lymph nodes or distant organs.
Interventions
- BIOLOGICAL CG0070 Adenovirus Vector
- OTHER Control Arm: Quadruple Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438112
The ClinicalTrials.gov registry entry for NCT01438112 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CG Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CG0070 Adenovirus Vector is the first listed.
NCT01438112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01438112 about?
NCT01438112 is a clinical study titled "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer". The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis t...
What is the current status of trial NCT01438112?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01438112?
The interventions under investigation include: CG0070 Adenovirus Vector (BIOLOGICAL), Control Arm: Quadruple Choice (OTHER).
Who is sponsoring clinical trial NCT01438112?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.